The company uses a proprietary computational engine to identify patient cohorts and determine therapeutic designs. By analyzing disease-causing mutations, Skip Therapeutics can identify treatable patient populations and optimize target selection. They leverage recent advancements in RNA-therapeutics to restore protein function of mutated genes, using splice modulating antisense oligonucleotides (ASOs). This approach offers a rapid and cost-effective solution for developing dedicated treatments for the millions of people worldwide affected by rare genetic disorders.